Toinv wrote "What are the implications of "acute phase response"? Does this have some sort of clinical relevance?"

Resverlogix has published papers and posters with some of their acute phase response (APR) findings. Their annual information form from a couple months ago suggests an APR-centered manuscript is going to be published soon.

"Currently,  an  additional  manuscript  has  been  accepted  with  revisions  to  the  Journal of  Translational Medicine,  titled  “Epigenetic modulation by  apabetalone  counters  cytokine  driven  acute  phase  response  in  vitro,  in mice  and  in cardiovascular  disease patients”. This  work  compiles  all  findings  to  date  regarding  apabetalone’s  effects  on the  acute  phase  response,  related  targets and  pathways."

So we should see the full APR story soon instead of the bits and pieces prior. APR is part of the immune/inflammatory response often characterized by changes to particular circulating protein in the blood.

Yes, very clinically relevant. Over time, it seems that Resverlogix has moved from discussing general anti-inflammatory effects of apabetalone to specifically focusing on localized vascular inflammation separately from changes in systemic, circulating inflammatory markers (APR, hsCRP etc.)

BDAZ